A Phase 3 interventional study of Lurasidone and Matching Placebo in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 75 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-08.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 18 in phase 3, and was the 17th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
This study's enrollment of 676 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2011, is one of 21 in phase 3, and was the 18th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Open Label:
Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.
Subject is ≥ 18 and ≤ 75 years of age, on the day of signing the informed consent.
Subject meets criteria for a primary diagnosis of schizophrenia [including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes as established by clinical interview (using the DSM-IV-TR as a reference and confirmed using the SCID-CT)]. The duration of the subject's illness whether treated or untreated must be ≥ 1 year.
Subject has had at least one prior episode of psychotic exacerbation as judged by the Investigator in the two years preceding screening.
Subject has a PANSS Total score ≥ 80 with a score ≥ 4 on 1 or more of any PANSS Positive subscale items at screening and open-label baseline (Visit 2).
Subject has a CGI-S score of ≥ 4 at screening and open-label baseline (Visit 2).
Subject is not pregnant (must have a negative serum pregnancy test at screening) or nursing (must not be lactating) and is not planning pregnancy within the projected duration of the study.
Female subject of agrees to remain abstinent or use adequate and reliable throughout the study and for at least 30 days after the last dose of lurasidone has been taken. In the Investigator's judgment, the subject will adhere to this requirement.
Adequate contraception is defined as continuous use of either two barrier methods (e.g., condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive. Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening.
Subjects who are of non-reproductive potential, i.e., subject who is surgically sterile, has undergone tubal ligation, or is (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis) are not required to remain abstinent or use adequate contraception.
Subject is able and agrees to remain off prior antipsychotic medication for the duration of the study.
Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge, if hospitalized. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (e.g., due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.
Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening.
Subject who requires concomitant medication treatment with the following agents may be included if they have been on stable doses (i.e., minor adjustments only) for the specified times: 1) antidepressant agents (except fluvoxamine) and/or mood stabilizers (except carbamazepine or oxcarbazepine) must be stable for at least 30 days prior to open-label baseline, 2) oral hypoglycemics must be stable for at least 30 days prior to screening, 3) antihypertensive agents must be stable for at least 30 days prior to screening, and 4) thyroid hormone replacement must be stable for at least 90 days prior to screening. (Note: inducers and inhibitors will not be allowed).
Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator.
Double-blind -
Subject must achieve and maintain clinical stability for a total of at least 12 weeks in the open label phase, defined as:
a PANSS Total score ≤ 70, a CGI-S score \< 4 and a PANSS item score of ≤ 4 (moderate or less) on all PANSS Positive subscale items over at least 12 weeks with the allowance of two excursions (except during the last 4 weeks of the open-label phase) assessed at weekly study visits:
Exclusion Criteria:
Open Label - Subject has a Axis I or Axis II diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.
Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (in the past month) or baseline.
Subject has attempted suicide within 3 months prior to the screening phase. Subject currently has a medical condition including the following: neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorder such as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study. Subjects with (HIV) seropositivity (or history of seropositivity) will be excluded.
Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor before being screened.
Subject has evidence of any chronic organic disease of the CNS such as tumors, inflammation, and active seizure disorder, vascular disorder, Parkinson's disease, Alzheimer's disease or other forms of dementia, myasthenia gravis, or other degenerative processes. In addition, subject must not have a history of mental retardation or persistent neurological symptoms attributable to serious head injury. Note: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.
Note: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.
Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.
Note: Subjects with serum (ALT) or aspartate transaminase (AST) levels ≥ 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, such subjects will be discussed with the Medical Monitor for enrollment consideration.
Subject has a history of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug.
Subject with Type 1 or Type 2 insulin-dependent diabetes.
Subject with newly diagnosed Type 2 diabetes during screening. Subject with Type 2 diabetes is eligible for study inclusion if the following condition is met at screening:
if a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.
Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or ≥ 7.0% will be excluded.
Note: Subjects with random (non-fasting) blood glucose at screening ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state.
Subject has a prolactin concentration > 100 ng/mL at screening or has a history of pituitary adenoma.
Subject has a history of \< 5 years prior to signing the , except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
Subject is judged to be resistant to antipsychotic treatment defined as any one of the following:
Subject is receiving an antipsychotic medication above the maximum recommended (country-specific) dose at or prior to screening and, in the judgment of the Investigator, is unlikely to respond to standard doses of lurasidone.
Subject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer) prior to the screening phase.
Subject has received treatment with MAO inhibitors within 14 days prior to the screening phase.
Subject requires treatment with any potent inhibitors or inducers during the study (see Appendix 3).
Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require electroconvulsive therapy (ECT) during the study.
Subject has a history of neuroleptic malignant syndrome. Subject exhibits evidence of severe tardive dyskinesia, severe dystonia, or any other severe movement disorder. Severity will be determined by the Investigator.
Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.
Subject tests positive for drugs of abuse at screening. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this drug during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
Subject had a history or presence of an abnormal (ECG), which in the Investigator's opinion is clinically significant (Medical Monitor may be consulted to determine clinical significance).
Subject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator.
Subject has a history of to more than 2 distinct chemical classes of drug (e.g., sulfas and penicillins).
Subject was screened or washed out previously more than three times for this study.
Subject is currently participating, or has participated in, a study with an or marketed compound or device within 3 months prior to signing the informed consent, or has participated in 2 or more studies within 12 months prior to signing the informed consent.
Subject is homeless or did not have a stable residence for the 3 months prior to the screening phase.
Subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or was planning to relocate during the study.
Subject requires guardianship under the laws of his/her country.
Double-blind - Subjects who in the Investigator's judgment have not been compliant with study medication during the open-label stabilization phase.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Drug: Lurasidone
Matching placebo once daily in the evening with a meal or 30 minutes after eating
Drug: Matching Placebo
Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Also known as: Latuda
Matching placebo once daily in the evening with a meal or 30 minutes after eating
Time to First Relapse Event During Double-blind Phase
The Kaplan-Meier method is used for the estimation.
Time frame: Double-blind phase - 28 Weeks
Time to All-cause Discontinuation
The Kaplan-Meier method was used for estimation.
Time frame: Double-blind phase - 28 weeks
Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
Time frame: Double-Blind phase - 28 Weeks
Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
Time frame: Double-blind phase - 28 Weeks
Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
Time frame: Double-blind phase - 28 Weeks
Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score
The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Time frame: Double-blind phase - 28 Weeks
Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score
The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.
Time frame: Double-blind phase - 28 Weeks
Brief Adherence Rating Scale
The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.
Time frame: Double-blind phase - 28 Weeks
Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)
Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.
Time frame: 28 Weeks - Double Blind Phase
Intent to Attend (ITA) Assessment at Open-label Baseline
The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: "How likely is it that you will complete the study?"
Time frame: Open Label Baseline
EuroQol (EQ-5D): EQ-VAS Score
The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating. The 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.
Time frame: Double-blind phase - 28 Weeks
| Milestone | All Subjects | Lurasidone | Placebo |
|---|---|---|---|
| Started | 676 | 0 | 0 |
| Completed | 287 | 0 | 0 |
| Not completed | 389 | 0 | 0 |
| Withdrew: Adverse event | 83 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 46 | 0 | 0 |
| Withdrew: Lost to follow-up | 60 | 0 | 0 |
| Withdrew: Protocol violation | 39 | 0 | 0 |
| Withdrew: Withdrawal by subject | 96 | 0 | 0 |
| Withdrew: Did not meet stabilization criteria | 44 | 0 | 0 |
| Withdrew: Terminated at study completion | 6 | 0 | 0 |
| Withdrew: Administrative | 14 | 0 | 0 |
| Milestone | All Subjects | Lurasidone | Placebo |
|---|---|---|---|
| Started | 0 | 144 | 141 |
| Completed | 0 | 28 | 20 |
| Not completed | 0 | 116 | 121 |
| Withdrew: Adverse event | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 5 |
| Withdrew: Protocol violation | 0 | 11 | 4 |
| Withdrew: Withdrawal by subject | 0 | 5 | 12 |
| Withdrew: Terminated at study completion | 0 | 47 | 39 |
| Withdrew: Relapse criteria met | 0 | 43 | 58 |
| Withdrew: Administrative | 0 | 5 | 2 |
The Kaplan-Meier method is used for the estimation.
| days | Lurasidone | Placebo |
|---|---|---|
| Time to First Relapse Event During Double-blind Phase | NA (174 to NA) | 192 (113 to NA) |
The Kaplan-Meier method was used for estimation.
| days | Lurasidone | Placebo |
|---|---|---|
| Time to All-cause Discontinuation | 148 (106 to NA) | 115 (82 to 148) |
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score | 8.3 ± 1.33 | 12.4 ± 1.33 |
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score | 0.44 ± 0.087 | 0.74 ± 0.087 |
The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | 2.5 ± 0.63 | 3.6 ± 0.63 |
The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score | 0.398 ± 0.5354 | -1.341 ± 0.5373 |
The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score | 0.8 ± 0.88 | 3.2 ± 0.89 |
The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.
| percentage of monthly doses taken | Lurasidone | Placebo |
|---|---|---|
| Brief Adherence Rating Scale | 98.8 ± 4.42 | 98.9 ± 3.66 |
The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating. The 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| EuroQol (EQ-5D): EQ-VAS Score | 74.5 ± 19.87 | 68.2 ± 28.59 |
Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.
| number of cigarettes smoked daily | Lurasidone | Placebo |
|---|---|---|
| Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF) | 10.0 ± 12.76 | 8.2 ± 8.97 |
The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: "How likely is it that you will complete the study?"
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Intent to Attend (ITA) Assessment at Open-label Baseline | 7.9 ± 1.48 | 8.0 ± 1.47 |
Collected over For the open label phase - all subjects SAEs and AEs were reported over 24 weeks. For the double blind phase, lurasidone and placebo, SAEs and AEs were reported over 28 weeks. The study was stopped once the anticipated number of relapses were reached.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | — | 59/676 (8.7%) | 373/676 (55.2%) |
| Lurasidone | — | 6/144 (4.2%) | 46/144 (31.9%) |
| Placebo | — | 11/141 (7.8%) | 47/141 (33.3%) |
| Event | All Subjects | Lurasidone | Placebo |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 20/676 | 1/144 | 4/141 |
| Psychotic disorderPsychiatric disorders | 11/676 | 2/144 | 2/141 |
| Angina pectorisCardiac disorders | 0/676 | 0/144 | 1/141 |
| Artial fibrillationCardiac disorders | 0/676 | 0/144 | 1/141 |
| Non-cardiac chest painGeneral disorders | 0/676 | 0/144 | 1/141 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/676 | 0/144 | 1/141 |
| Suicide attemptPsychiatric disorders | 1/676 | 0/144 | 1/141 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/676 | 1/144 | 0/141 |
| Pin in extremityMusculoskeletal and connective tissue disorders | 0/676 | 1/144 | 0/141 |
| HeadacheNervous system disorders | 0/676 | 1/144 | 0/141 |
| Event | All Subjects | Lurasidone | Placebo |
|---|---|---|---|
| AkathisiaNervous system disorders | 94/676 | 3/144 | 4/141 |
| HeadacheNervous system disorders | 77/676 | 4/144 | 5/141 |
| NauseaGastrointestinal disorders | 69/676 | 3/144 | 1/141 |
| InsomniaPsychiatric disorders | 62/676 | 9/144 | 10/141 |
| SchizophreniaPsychiatric disorders | 4/676 | 10/144 | 11/141 |
| VomitingGastrointestinal disorders | 36/676 | 1/144 | 0/141 |
| AnxietyPsychiatric disorders | 35/676 | 6/144 | 4/141 |
| SomnolenceNervous system disorders | 34/676 | 0/144 | 0/141 |
| Psychotic disorderPsychiatric disorders | 4/676 | 4/144 | 6/141 |
| Back painMusculoskeletal and connective tissue disorders | 17/676 | 6/144 | 3/141 |
| Age, Continuous(years) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Mean | 43.0 ± 11.38 | 42.4 ± 12.25 | 42.7 ± 11.80 |
| Age, Categorical(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 142 | 140 | 282 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Female | 54 | 53 | 107 |
| Male | 90 | 88 | 178 |
| Race (NIH/OMB)(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 72 | 62 | 134 |
| White | 65 | 71 | 136 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 16 |
| Not Hispanic or Latino | 137 | 132 | 269 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| France | 3 | 2 | 5 |
| Serbia | 9 | 11 | 20 |
| United States | 103 | 97 | 200 |
| Slovakia | 11 | 11 | 22 |
| Russian Federation | 7 | 9 | 16 |
| South Africa | 10 | 11 | 21 |
| Italy | 1 | 0 | 1 |
The record gives a start of Sep 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →